FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3026644766> ?p ?o ?g. }

• W3026644766 endingPage "404" @default.
• W3026644766 startingPage "398" @default.
• W3026644766 abstract "Evaluar el efecto de amlodipino sobre las hospitalizaciones por enfermedades cardiovasculares y sus costes asociados en pacientes con cardiopatía isquémica. Se utilizaron los datos del ensayo clínico multicéntrico, randomizado, doble ciego controlado con placebo PREVENT (Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial). Se utilizó un modelo de decisión tipo árbol para analizar los costes incrementales esperados del tratamiento con amlodipino sobre placebo. Los costes de hospitalización se dedujeron en relación con los pesos de los GRD del Medicare americano adaptados a los costes de estancia media disponibles en nuestro entorno. Amlodipino redujo significativamente la incidencia de enfermedades vasculares que requieren hospitalización frente a placebo; 0,60 ± 1,16 frente a 0,77 ± 1,31 (media ± DE), p < 0,05. Los costes directos esperados debidos a hospitalizaciones fueron mayores en el grupo de placebo que en el de amlodipino (ahorro de 205,76 € por paciente). El coste total por paciente para amlodipino fue 1.723,52 € mientras que para placebo fue de 1.929,28 €. Cuando la relación coste/precio varió en el análisis de sensibilidad desde 1,20 a 0,66 (el coste de cada hospitalización varió entre + 20% y –34%), el ahorro osciló desde 330,56 € a 0. Por tanto, el punto de equilibrio de la relación coste/precio es 0,66 por encima del cual el tratamiento con amlodipino aún genera ahorros con relación a su coste. Amlodipino es coste-efectivo en la terapéutica del paciente con cardiopatía isquémica, pudiendo reducir los costes hospitalarios relacionados con episodios isquémicos en este tipo de pacientes. Evaluation of the effect of amlodipine on the hospitalizations for cardiovascular events (CVE) and their associated costs in patients with ischemic cardiopathy. Data from the multicenter, randomized, double-blind, placebo-controlled PREVENT (Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial) clinical trial were utilized. A tree-type model of decision was used in order to analyze the incremental costs expected from the treatment with amlodipine with regard to placebo. Hospitalization costs were estimated with regard to the DRG weights of the American Medicare adapted for the costs of average stay available in our environment. Amlodipine reduced significantly the incidence of CVE that required hospitalization in contrast to placebo; 0.60 ± 1.16 versus 0.77 ± 1.31 (average ± SD), p < 0.05. The expected direct expenses due to hospitalizations were higher in the placebo group than in the amlodipine group (saving of 205.76 €/patient). Total cost for patient in the amlodipine group was 1,723.52 € while in the placebo group was 1,929.28 €. When the relation cost/price shifted in the sensitivity analysis from 1.20 to 0.66 (cost of every hospitalization ranged between + 20% and –34%), the saving fluctuated from 330.56 € to 0. Accordingly, the breakeven point of the cost/price relation it is 0.66, and above this the treatment with amlodipine still generates savings in regard to its cost. Amlodipine is cost-effective in the treatment of the patients with ischemic cardiopathy, being able to reduce the hospital costs related to ischemic episodes in this type of patients." @default.
• W3026644766 created "2020-05-29" @default.
• W3026644766 creator A5026798178 @default.
• W3026644766 creator A5030691321 @default.
• W3026644766 creator A5036097459 @default.
• W3026644766 creator A5052789438 @default.
• W3026644766 creator A5079965170 @default.
• W3026644766 creator A5090323723 @default.
• W3026644766 date "2004-08-01" @default.
• W3026644766 modified "2023-10-03" @default.
• W3026644766 title "Análisis de la eficacia y costes de amlodipino sobre las hospitalizaciones por eventos cardiovasculares en pacientes con cardiopatía isquémica" @default.
• W3026644766 doi "https://doi.org/10.1157/13064312" @default.
• W3026644766 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15274762" @default.
• W3026644766 hasPublicationYear "2004" @default.
• W3026644766 type Work @default.
• W3026644766 sameAs 3026644766 @default.
• W3026644766 citedByCount "1" @default.
• W3026644766 crossrefType "journal-article" @default.
• W3026644766 hasAuthorship W3026644766A5026798178 @default.
• W3026644766 hasAuthorship W3026644766A5030691321 @default.
• W3026644766 hasAuthorship W3026644766A5036097459 @default.
• W3026644766 hasAuthorship W3026644766A5052789438 @default.
• W3026644766 hasAuthorship W3026644766A5079965170 @default.
• W3026644766 hasAuthorship W3026644766A5090323723 @default.
• W3026644766 hasConcept C138885662 @default.
• W3026644766 hasConcept C142724271 @default.
• W3026644766 hasConcept C15708023 @default.
• W3026644766 hasConcept C204787440 @default.
• W3026644766 hasConcept C27081682 @default.
• W3026644766 hasConcept C29456083 @default.
• W3026644766 hasConcept C71924100 @default.
• W3026644766 hasConceptScore W3026644766C138885662 @default.
• W3026644766 hasConceptScore W3026644766C142724271 @default.
• W3026644766 hasConceptScore W3026644766C15708023 @default.
• W3026644766 hasConceptScore W3026644766C204787440 @default.
• W3026644766 hasConceptScore W3026644766C27081682 @default.
• W3026644766 hasConceptScore W3026644766C29456083 @default.
• W3026644766 hasConceptScore W3026644766C71924100 @default.
• W3026644766 hasIssue "8" @default.
• W3026644766 hasLocation W30266447661 @default.
• W3026644766 hasLocation W30266447662 @default.
• W3026644766 hasOpenAccess W3026644766 @default.
• W3026644766 hasPrimaryLocation W30266447661 @default.
• W3026644766 hasRelatedWork W1995515455 @default.
• W3026644766 hasRelatedWork W1999344589 @default.
• W3026644766 hasRelatedWork W2039318446 @default.
• W3026644766 hasRelatedWork W2080531066 @default.
• W3026644766 hasRelatedWork W2151856280 @default.
• W3026644766 hasRelatedWork W2748952813 @default.
• W3026644766 hasRelatedWork W2789448498 @default.
• W3026644766 hasRelatedWork W2899084033 @default.
• W3026644766 hasRelatedWork W3032375762 @default.
• W3026644766 hasRelatedWork W4233016836 @default.
• W3026644766 hasVolume "204" @default.
• W3026644766 isParatext "false" @default.
• W3026644766 isRetracted "false" @default.
• W3026644766 magId "3026644766" @default.
• W3026644766 workType "article" @default.